Niagen Bioscience (NAGE) Cash from Operations Growth (5y) (2016 - 2026)
Niagen Bioscience (NAGE) Cash from Operations Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Niagen Bioscience | 259.33 Mn | 192.78 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.07% |
| Dec 31, 2025 | 100.00% |
| Sep 30, 2025 | 24.26% |
| Jun 30, 2025 | 22.71% |
| Mar 31, 2025 | 28.55% |
| Dec 31, 2024 | 74.26% |
| Sep 30, 2024 | 19.63% |
| Jun 30, 2024 | 50.65% |
| Mar 31, 2024 | 15.96% |
| Dec 31, 2023 | 16.29% |
| Sep 30, 2023 | 15.73% |
| Jun 30, 2023 | 20.12% |
| Mar 31, 2023 | 21.97% |
| Dec 31, 2022 | 38.63% |
| Sep 30, 2022 | -51.09% |
| Jun 30, 2022 | 7.01% |
| Mar 31, 2022 | -169.11% |
| Dec 31, 2021 | -94.53% |
| Sep 30, 2021 | -111.34% |
| Jun 30, 2021 | -143.98% |